Title: Biomarker discovery by NexGen Sequencing of Immune Repertoire

Presenter: HAN Jian

University:  Hudson Alpha Institute for Biotechnology

Time: 10:00-11:30, October 29, 2012

Venue: Room A203, Institute of Microbiology, Chinese Academy of Sciences

Introduction of the Presenter:

Director, Repertoire 10K Project (“R10K”)

Faculty investigator, Hudson Alpha Institute for Biotechnology 2007-present

CEO, iRepertoire; President and CSO, iCubate 2009-present

R&D director, Molecular Diagnostics, Qiagen 2006-2007

CSO, President, Genaco, 2004-2006

CEO, President, Genaco, 1996-2004

Director, Clinical molecular Genetics Laboratory, UAB, 1994-1996

Abstract:

Deep profiling of CDR3s with high throughput sequencing is a powerful approach to uncover the composition and distribution of CDR3s in a given sample with details at the sequence level. The “R10K” project aims to sequence the immune repertoire of 10,000 individuals that represent 100 diseases. Our goal is to identify disease-specific T or B cell receptor sequences for diagnosis and treatment management. The project, lead by the nonprofit HudsonAlpha Institute, is an international collaborative effort. Four categories of diseases and conditions will be studied: cancer, autoimmune diseases, inflammatory diseases and infectious diseases/vaccines.

To estimate the diversity of T-cell receptors in healthy individuals, we have sequenced CDR3s amplified from panT, CD4+ T and CD8+ T cell populations isolated from 100 healthy subjects. Details of CDR3s in those healthy subjects will be discussed, and progress of the project will be reported.